Zealand Pharma A/S/ DK0060257814 /
2024-05-16 7:57:07 AM | Chg. +0.7000 | Volume | Bid9:59:59 PM | Ask9:59:59 PM | High | Low |
---|---|---|---|---|---|---|
87.2500EUR | +0.81% | - Turnover: - |
82.0000Bid Size: 48 | 82.8000Ask Size: 48 | 87.2500 | 87.2500 |
GlobeNewswire
05-09
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...
GlobeNewswire
03-20
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire
02-26
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...
GlobeNewswire
02-26
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...
GlobeNewswire
02-20
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financia...
GlobeNewswire
01-08
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
GlobeNewswire
01-02
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on Janua...
GlobeNewswire
2023-12-23
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyp...
GlobeNewswire
2023-12-22
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
GlobeNewswire
2023-12-22
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
GlobeNewswire
2023-11-30
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
GlobeNewswire
2023-11-09
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
GlobeNewswire
2023-11-07
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023